Vosoritide
Vosoritide (Voxzogo)
Vosoritide (brand name Voxzogo) is a synthetic analog of C-type natriuretic peptide (CNP) approved by the FDA in 2021 for the treatment of achondroplasia, the most common form of dwarfism, in pediatric patients with open epiphyseal growth plates. It is a 39-amino acid peptide that promotes endochondral bone growth and is the first pharmacological treatment specifically indicated to increase linear growth in children with achondroplasia.
Mechanism of Action
Vosoritide mimics endogenous CNP by binding to natriuretic peptide receptor B (NPR-B) on chondrocytes in the growth plate, activating guanylyl cyclase and increasing intracellular cGMP levels. This downstream signaling inhibits the MAPK/ERK pathway, which counteracts the overactive FGFR3 signaling caused by the achondroplasia-causing FGFR3 gain-of-function mutation, thereby restoring more normal chondrocyte proliferation and differentiation to enhance longitudinal bone growth.
Evidence by Health Goal(12 goals)
Dosing Protocols
At approximately the same time each day; rotate subcutaneous injection sites
Administered as a subcutaneous injection. Dose is weight-based at 15 mcg/kg/day. Intended for pediatric patients with open growth plates; treatment is ongoing until growth plate closure. Reconstituted solution should be used immediately or stored refrigerated for up to 24 hours.
Safety & Side Effects
Vosoritide has a generally acceptable safety profile in its approved pediatric population, with the most clinically significant risk being transient hypotension post-injection, which warrants monitoring particularly in the first weeks of treatment. It is an FDA-approved prescription-only medication; off-label use outside of achondroplasia or in adults with closed growth plates lacks clinical evidence and is not supported.
Possible Side Effects
- !Injection site reactions (erythema, bruising, pruritus) - most common adverse effect reported in trials
- !Transient decrease in blood pressure (symptomatic hypotension) shortly after injection
- !Vomiting
- !Fatigue
- !Abdominal pain
- !Hypersensitivity reactions including rash and urticaria
- !Decreased blood pressure leading to dizziness or presyncope
Interactions
- -Additive hypotensive effect with antihypertensive medications - monitor blood pressure closely
- -Potential enhanced hypotension with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil) due to convergent cGMP pathway activity
- -Use with other natriuretic peptide analogs or vasodilatory agents may compound blood pressure lowering
- -No specific CYP450 interactions identified, but co-administration with other vasoactive peptides warrants caution
Cost & Where to Buy
Vosoritide is an extremely high-cost branded biopharmaceutical; list price is approximately $320,000-$400,000 per year. Actual out-of-pocket cost varies significantly based on insurance coverage and patient assistance programs offered by BioMarin. Not available as a generic or from standard research peptide vendors.
Search on Amazon